Abstract:Objectives The main aim of our study is to observe clinical characteristics and effects of antihypertensive drugs in different hospitalized populations, and to further provide evidence to explore causes and specific clinical markers of the aggravation of COVID-19 in patients with underlying hypertension. Design This was a retrospective cohort study focusing on the clinical data of COVID-19 inpatients admitted at the early stage of pandemic. Setting A single center study conducted in Tongji Hospital, Tongji Medical College of Huazhong university of Science and Technology (Wuhan, China). Participants All 1031 inpatients diagnosed with COVID-19 according to Prevention and control Scheme for Novel Coronavirus Pneumonia published by National Health Commission of the People’s Republic of China and WHO interim guidance in Tongji hospital (Wuhan, China), from January 27, 2020, to March 8, 2020 with the cutoff date being March 30, 2020, were included in this study. Main outcome measures Demographic data, medical history, clinical symptoms and signs, laboratory findings, chest computed tomography (CT), treatment, and clinical outcomes were extracted from electronic medical records. Results 1031 COVID-19 inpatients were included in this study, of whom 866 were discharged and 165 were deceased in hospital. 73% of 165 deceased patients had chronic comorbidities. Patients with underlying diseases showed CFR 2.8 times as that of patients without. Senility and males were observed to be main risk factors for increased in-hospital case-fatality rate, with the odds ratio in multivariable regression being 2.94 (95%CI: 2.00 to 4.33; P <0.001) and 2.47 (95%CI: 1.65 to 3.70; P <0.001), respectively. The odds ratio of cases with composite endpoints for patients with simple hypertension was 1.53 (95%CI: 1.07 to 2.17; P=0.019). Senile patients with hypertension were proved to be at high risk early in the disease, which might be associated with the level of CRP, LDH, and eGFR. The odds ratio of case-fatality rate for patients with hypertension taking CCB group was 0.67 (95%CI: 0.37 to 1.20; P = 0.176). Among 271 severe cases without IKF, the odds ratio of case-fatality rate was 0.42 (95CI%: 0.18 to 0.99; P = 0.046) for patients in the CCB group after adjustment of age, sex, and underlying diseases. Conclusions Hypertension is not just a chronic underlying comorbidity, but also a risk factor affecting the severity of COVID-19 and does play a critical role in worsening patients’ clinical outcomes. Therefore, hypertension management in patients with COVID-19 should be regarded as a major challenge in the diagnostic and therapeutic strategies. Trial registration N.A. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The study was supported by COVID-19 Emergency Response Project of Wuhan Science and Technology Department (2020020201010018). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of Tongji Hospital, Wuhan, China, approved this retrospective study and written informed consent was waived (No. TJ-C20200140). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The raw data was extracted from electronic medical records with standardized data collection forms in Tongji Hospital (Wuhan, China), which had been approved by the Research Ethics Commission of Tongji Hospital, Tongji medical college of HUST. The data used to support the findings of this study are available from the corresponding author upon request. * ACI : Acute cardiac injury ALT : Alanine aminotransferase APTT : Activated partial thromboplastin time AST : Aspartate aminotransferase CCB : Calcium channel blockers CCIR : Case-critically ill rate CDC : Chinese Center for Disease Control and Prevention CFR : Case-fatality rate CHD : Coronary atherosclerotic heart disease COPD : Chronic obstructive pulmonary disease COVID-19 : Coronavirus disease 2019 CRPC : -reactive protein CRRT : Continuous renal replacement therapy DM : Diabetes mellitus ECMO : Extracorporeal membrane oxygenation eGFR : Glomerular filtration rate ESR : Erythrocyte sedimentation rate IKF : Impaired kidney function IL-6 : Interleukin 6 LDH : Lactate dehydrogenase LOS : Length of stay MAP : Mean arterial pressure NT-proBNP : N-terminal pro-brain natriuretic peptide OOS : Oximeter oxygen saturation PT : Prothrombin time RAS : Renin-angiotensin-aldosterone system RASI : Renin-angiotensin-aldosterone system inhibitors SARS-CoV-2 IgG : SARS-CoV-2 Immunoglobulin G SARS-CoV-2 IgM : SARS-CoV-2 Immunoglobulin M Scr : Serum creatinine TNI : Troponin I WHO : World Health Organization

Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension

SARS-CoV-2-specific T cell immunity in mild hypertensive patients with COVID-19 in China

Hypertension as a sequela in patients of SARS-CoV-2 infection

Hypersensitivity May Be Involved in Severe COVID-19.

Role of Hypertension on the Severity of COVID-19: A Review

Clinical Course and Outcomes of COVID-19 Patients with Hypertension

Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients

COVID-19 patients with hypertension are at potential risk of worsened organ injury

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients

Dynamic blood single-cell immune responses in patients with COVID-19

Impact of Hypertension on Progression and Prognosis in Patients with COVID-19 A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China

Impact of Chronic Comorbidities on Progression and Prognosis in Patients with COVID-19: A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China

Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients

Clinical Characteristics and Inflammatory Immune Responses in COVID-19 Patients With Hypertension: A Retrospective Study

Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis.

Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China

The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19

HYPERCOAGULATION OF BLOOD AND THROMBOCYTOPENIA AFTER SARS-COV-2 – PNEUMONIA AS PREDICTORS OF AN UNFAVORABLE PROGNOSIS IN PATIENTS WITH ARTERIAL HYPERTENSION